



766.46

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re Application of:)
HIROMASA MIYAJI ET AL.) : Examiner: N/Y/A
Application No.: 09/763,793) : Group Art Unit: N/Y/A
Filed: February 27, 2001) :
For: NOVEL POLYPEPTIDE) : Date: May 9, 2001

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. §§ 1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed Form PTO-1449. Copies of the listed documents are also enclosed.

CONCLUSION

It is respectfully requested that the above information be considered by the Examiner and that a copy of the enclosed Form PTO-1449 be returned indicating that such information has been considered.

PCT
9200/MOG

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our address given below.

Respectfully submitted,



Attorney for Applicants

Registration No. 31865

FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York 10112-3801
Facsimile: (212) 218-2200

ATTY DOCKET NO.
766.46APPLICATION NO.
09/763,793APPLICANT
Hiromasa Miyaji et al.FILING DATE
February 27, 2001GROUP
NYAMAY 10 2001
JC1586
PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
------------------	-----------------	------	------	-------	----------	----------------------------

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT
--	-----------------	------	---------	-------	----------	---------------------------------

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

(1)	Griffiths, M. et al., Cloning of a human nucleoside transporter implicated in cellular uptake of adenosine and chemotherapeutic drugs, Nature Medicine Vol. 3, No. 1 (1997), pages 89-93.
(2)	Yao, S.Y. et al., Molecular cloning and functional characterization of nitrobenzylthioinosine (NBMPR)-sensitive(es) and NBMPR-insensitive(ei) equilibrative nucleoside transporter proteins (rENT1 and rENT2) from rat tissues, Journal of Biological Chemistry Vol. 272, No. 45 (1997), pages 28423-28430.
(3)	Griffiths, M. et al., Molecular cloning and characterization of a nitrobenzylthioinosine-insensitive(ei) equilibrative, nucleoside transporter from human placenta, Biochem. J. Vol. 328, Pt. 3 (1997), pages 739-749.
(4)	Crawford, C. R. et al., Cloning of the human equilibrative, nitrobenzylmercaptopurine reboside (NBMPR)-insensitive nucleoside transporter ei by functional expression in a transport-deficient cell line, J. Biol. Chem. Vol. 273, No. 9 (Feb. 1998) pages 5288-5293.
(5)	Griffith, D. A. et al., Nucleoside and nucleobase transport systems of mammalian cells, Biochim. Biophys. Acta Vol. 1286, No. 3 (1996), pages 153-181
(6)	Belardinelli, L. et al., Adenosine and adenine nucleotides: from molecular biology to integrative physiology, pages 49-54, 55-60, 373-378.
(7)	Buolamwini, J. K., Nucleoside Transport Inhibitors: Structure-activity Relationships and Potential Therapeutic Applications, Current Medicinal Chemistry, Vol. 4, No. 1 (1997), pages 35-66.
(8)	Clumeck, N., Current use of anti-HIV drugs in AIDS, Journal of Antimicrobial Chemotherapy 32, Suppl. A (1993), pages 133-138.
(9)	Belardinelli, L. et al., The Cardiac Effects of Adenosine, Progress in Cardiovascular Diseases Vol. XXXIII, No. 1 (July/August 1989), pages 73-97.
(10)	Jacobson, K. A. et al., Purines in Cellular Signaling: Targets for New Drugs, pages 20-33, 174-183.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 1 of 1